BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 9422559)

  • 1. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
    Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of etanidazole and radiotherapy in malignant glioma.
    Riese NE; Loeffler JS; Wen P; Alexander E; Black PM; Coleman CN
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):617-20. PubMed ID: 8005825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
    Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
    Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
    Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
    Levin VA; Yung WK; Bruner J; Kyritsis A; Leeds N; Gleason MJ; Hess KR; Meyers CA; Ictech SA; Chang E; Maor MH
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):58-66. PubMed ID: 12007942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
    Prados MD; Scott C; Sandler H; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1109-15. PubMed ID: 10613302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
    Jeremic B; Shibamoto Y; Grujicic D; Stojanovic M; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J
    J Neurooncol; 2001 Jan; 51(2):133-41. PubMed ID: 11386410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
    Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience.
    Chun M; McKeough P; Wu A; Kasdon D; Heros D; Chang H
    Br J Radiol; 1989 Feb; 62(734):158-62. PubMed ID: 2538197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
    Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.
    Sullivan FJ; Herscher LL; Cook JA; Smith J; Steinberg SM; Epstein AH; Oldfield EH; Goffman TE; Kinsella TJ; Mitchell JB
    Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):583-90. PubMed ID: 7928489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
    Groves MD; Maor MH; Meyers C; Kyritsis AP; Jaeckle KA; Yung WK; Sawaya RE; Hess K; Bruner JM; Peterson P; Levin VA
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):127-35. PubMed ID: 10477016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival?
    Laramore GE; Martz KL; Nelson JS; Griffin TW; Chang CH; Horton J
    Int J Radiat Oncol Biol Phys; 1989 Dec; 17(6):1351-6. PubMed ID: 2689399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
    Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
    Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme.
    Krishnasamy S; Vokes EE; Dohrmann GJ; Mick R; Garcia JC; Kolker JD; Wollmann RL; Hekmatpanah J; Weichselbaum RR
    Cancer Invest; 1995; 13(5):453-9. PubMed ID: 7552809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
    Jeremic B; Jovanovic D; Djuric LJ; Jevremovic S; Mijatovic LJ
    J Chemother; 1992 Apr; 4(2):123-6. PubMed ID: 1321239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.